Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality. Cases of EC in China account for over 50% of the global total, with squamous cell carcinoma being the primary pathological type. Locally advanced EC (LAEC), particularly cases where radical surgical resection is not feasible, exhibits high recurrence rates and low 5-year survival rates. However, studies have shown that patients with LAEC who undergo comprehensive treatment followed by surgery experience significantly prolonged survival and improved quality of life

Trial Details

NCT ID
NCT07339488
Phase
PHASE2
Sponsor
Chuangzhen Chen
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Intestinal Low Dose Radiotherapy-1Gy
  • PD-1/PD-L1 inhibitors
  • Chemotherapy
  • Surgery
Locations (sample)
  • Shantou, Guangdong, China|23.35489,116.67876

Key Eligibility Criteria

  • Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance.
  • Age ≥18 years and ≤75 years; both sexes are eligible.
  • ECOG performance status score of 0-1.
  • Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →